Thomas Hanke

Dr. Thomas Hanke

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Cell Chemical Biology
Verified
Journal Article
Open access
JVJames D. Vasta
James D. Vasta
CCCesear R. Corona
Cesear R. Corona
JWJennifer Wilkinson
Jennifer Wilkinson
CZChad A. Zimprich
Chad A. Zimprich
JHJames R. Hartnett
James R. Hartnett
MRMatthew B. Robers
Matthew B. Robers
For kinase inhibitors, intracellular target selectivity is fundamental to pharmacological mechanism. Although a number of acellular techniques have been developed to measure kinase binding or enzymatic inhibition, such approaches can fail to accurately predict engagement in cells. Here we report the application of an energy transfer technique that enabled the first broad-spectrum, equilibrium-based approach to quantitatively profile target occupancy and compound affinity in live cells. Using this method, we performed a selectivity profiling for clinically relevant kinase inhibitors against 178 full-length kinases, and a mechanistic interrogation of the potency offsets observed between cellular and biochemical analysis. For the multikinase inhibitor crizotinib, our approach accurately predicted cellular potency and revealed improved target selectivity compared with biochemical measurements. Due to cellular ATP, a number of putative crizotinib targets are unexpectedly disengaged in live cells at a clinically relevant drug dose.

20 April 2018 in eLife
Verified
Journal Article
Open access
SMSusanne Müller
Susanne Müller
SASuzanne Ackloo
Suzanne Ackloo
CACheryl H Arrowsmith
Cheryl H Arrowsmith
MBMarcus Bauser
Marcus Bauser
JBJeremy L Baryza
Jeremy L Baryza
AMAnke Mueller-Fahrnow
Anke Mueller-Fahrnow
Potent, selective and broadly characterized small molecule modulators of protein function (chemical probes) are powerful research reagents. The pharmaceutical industry has generated many high-quality chemical probes and several of these have been made available to academia. However, probe-associated data and control compounds, such as inactive structurally related molecules and their associated data, are generally not accessible. The lack of data and guidance makes it difficult for researchers to decide which chemical tools to choose. Several pharmaceutical companies (AbbVie, Bayer, Boehringer Ingelheim, Janssen, MSD, Pfizer, and Takeda) have therefore entered into a pre-competitive collaboration to make available a large number of innovative high-quality probes, including all probe-associated data, control compounds and recommendations on use (https://openscienceprobes.sgc-frankfurt.de/). Here we describe the chemical tools and target-related knowledge that have been made available, and encourage others to join the project.

2 June 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JAJennifer Alisa Amrhein
Jennifer Alisa Amrhein
SKStefan Knapp
Stefan Knapp
THThomas Hanke
Thomas Hanke

15 November 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
THThomas Hanke
Thomas Hanke
FDFriederike Dehm
Friederike Dehm
SLStefanie Liening
Stefanie Liening
SPSven-Desiderius Popella
Sven-Desiderius Popella
JMJonas Maczewsky
Jonas Maczewsky
OWOliver Werz
Oliver Werz

1 December 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AKAndreas Krämer
Andreas Krämer
CKChristian Georg Kurz
Christian Georg Kurz
Benedict-Tilman BergerBenedict-Tilman Berger
Benedict-Tilman Berger
ICIbrahim Ethem Celik
Ibrahim Ethem Celik
ATAmelie Tjaden
Amelie Tjaden
THThomas Hanke
Thomas Hanke

1 January 2016 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
THThomas Hanke
Thomas Hanke
DMDaniel Merk
Daniel Merk
DSDieter Steinhilber
Dieter Steinhilber
GGGerd Geisslinger
Gerd Geisslinger
MSManfred Schubert-Zsilavecz
Manfred Schubert-Zsilavecz